About Us

The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

LAWSUITS FILED AGAINST JRVR, OTLY and ARDX - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / August 17, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

James River Group Holdings, Ltd. (NASDAQ:JRVR)

CONTACT JAKUBOWITZ ABOUT JRVR:
https://claimyourloss.com/securities/james-river-group-holdings-ltd-loss-submission-form/?id=18633&from=1

Class Period : August 1, 2019 - May 5, 2021

Lead Plaintiff Deadline: September 7, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) James River had not adequately reserved for its Uber policies; (2) James River was using an incorrect methodology for setting reserves that materially understated the Company's true exposure to Uber claims; (3) as a result, James River was forced to increase its unfavorable reserves in subsequent quarters even after cancelling the Uber policies; and (4) as a result of the foregoing, Defendants' statements about James River's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Oatly Group AB (NASDAQ:OTLY)

CONTACT JAKUBOWITZ ABOUT OTLY:
https://claimyourloss.com/securities/oatly-group-ab-loss-submission-form/?id=18633&from=1

Class Period : May 20, 2021 - July 15, 2021

Lead Plaintiff Deadline: September 24, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) Oatly overinflated its gross margins, revenue, capital expenditure, and market share financial metrics; (b) the Company overstated its sustainability practices and impact; (c) the Company exaggerated its growth in China; and (c) as a result of the foregoing, Oatly's statements about its operations, business, and prospects were misleading during the Class Period.

Ardelyx, Inc. (NASDAQ:ARDX)

CONTACT JAKUBOWITZ ABOUT ARDX:
https://claimyourloss.com/securities/ardelyx-inc-loss-submission-form/?id=18633&from=1

Class Period : August 6, 2020 - July 19, 2021

Lead Plaintiff Deadline: September 28, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law
 



View source version on accesswire.com:
https://www.accesswire.com/660184/LAWSUITS-FILED-AGAINST-JRVR-OTLY-and-ARDX--Jakubowitz-Law-Pursues-Shareholders-Claims

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.